₹86.40
−4.99%NSE close, 16 Nov 2026
+5.55%
Bal Pharma is a small cap company, listed on NSE under the symbol BALPHARMA. At ₹86.40 a share, the market values the whole company at ₹138 crore.
In FY26, it reported sales of ₹312 crore and a net profit of ₹6 crore, an operating margin of 10.2%. Over the last three years, sales grew 0.8% a year and net profit grew 34.2% a year.
The market values the company at 17.4 times its profit over the last twelve months and 1.58 times its book value; its return on equity is 9.1% and its borrowings are 2.07 times its equity.
Promoters hold 50.86% of the shares. Foreign institutions hold 0.28%, and domestic institutions, mutual funds among them, 0.00%.
Over the past year the share price has risen 7.5%, and it is 30.7% below its 52-week high.
₹ crore. Consolidated figures.
Utilisation of Funds raised by Preferencial issue of Share warrants
Outcome of Board Meeting held on November 11, 2026.As intimated vide our letter dated November 03, 2026, Board of directors of the Company met on Wednesday, November 11, 2026 inter alia transacted the following business.1. Considered and approved the unaudited Financial…
The financial results for the period ended September 30, 2026.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 81.7 | 94.6 | 74.4 | 73.7 | 73.2 | 81.9 | 65.9 | 74.0 | 87.7 | 84.1 | 88.6 | 90.0 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 73.9 | 85.0 | 67.9 | 66.0 | 65.4 | 74.2 | 59.8 | 68.3 | 78.1 | 73.5 | 80.7 | 81.3 |
| Operating profit | 7.8 | 9.6 | 6.5 | 7.7 | 7.8 | 7.6 | 6.1 | 5.7 | 9.6 | 10.6 | 8.0 | 8.7 |
| Operating margin | 9.5% | 10.1% | 8.7% | 10.4% | 10.6% | 9.3% | 9.2% | 7.7% | 10.9% | 12.6% | 9.0% | 9.6% |
| Other income | 0.1 | 2.5 | 0.8 | −0.2 | 0.5 | 1.1 | 0.7 | 1.1 | 0.3 | −0.2 | 0.4 | 1.6 |
| Interest | 3.7 | 4.1 | 4.2 | 3.7 | 5.0 | 4.0 | 4.1 | 3.9 | 4.9 | 4.1 | 4.5 | 5.0 |
| Depreciation | 3.0 | 2.2 | 2.4 | 2.5 | 2.7 | 2.2 | 2.5 | 2.3 | 3.2 | 3.1 | 2.8 | 3.4 |
| Profit before tax | 1.3 | 5.8 | 0.6 | 1.4 | 0.6 | 2.6 | 0.2 | 0.7 | 1.8 | 3.2 | 1.1 | 1.9 |
| Tax | 0.4 | 0.2 | 0.4 | 0.3 | 0.1 | −2.8 | 0 | 0 | 0 | −0.4 | 0 | 0.5 |
| Net profit | 0.9 | 5.5 | 0.3 | 1.0 | 0.5 | 6.7 | 0.2 | 0.7 | 1.8 | 3.6 | 1.1 | 1.4 |
| EPS (₹) | 0.54 | 3.73 | 0.16 | 0.65 | 0.33 | 3.40 | 0.13 | 0.45 | 1.12 | 2.26 | 0.71 | 0.89 |
₹ crore, financial years to March.
| Line | FY18 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 212 | 171 | 251 | 281 | 304 | 339 | 303 | 312 |
| Expenses | 194 | 166 | 226 | 258 | 279 | 308 | 274 | 280 |
| Operating profit | 17.4 | 4.8 | 24.5 | 23.5 | 25.1 | 31.5 | 29.6 | 31.9 |
| Operating margin | 8.2% | 2.8% | 9.8% | 8.3% | 8.3% | 9.3% | 9.8% | 10.2% |
| Other income | 1.6 | 1.8 | 1.1 | 5.2 | 0.9 | 2.9 | 2.2 | 1.9 |
| Interest | 9.3 | 12.5 | 12.0 | 10.4 | 12.2 | 15.3 | 16.9 | 16.8 |
| Depreciation | 6.8 | 7.7 | 9.5 | 9.0 | 9.1 | 10.1 | 9.8 | 11.1 |
| Profit before tax | 2.9 | −13.5 | 4.1 | 9.2 | 4.7 | 9.1 | 5.1 | 5.9 |
| Tax | 2.5 | −0.6 | −0.6 | 3.5 | 2.1 | 1.6 | −2.1 | −0.4 |
| Net profit | 0.4 | −12.9 | 4.7 | 5.6 | 2.6 | 7.4 | 7.2 | 6.3 |
| EPS (₹) | 0.20 | -8.62 | 3.34 | 3.79 | 1.67 | 4.95 | 4.56 | 3.95 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 32.1 | 20.7 | 30.8 | −1.0 |
| From investing | 11.3 | −18.1 | −20.7 | −8.8 |
| From financing | 1.1 | 0.3 | −9.6 | 12.7 |
| Spent on fixed assets | 0 | 0 | −17.1 | −7.0 |
| Free cash flow | 32.1 | 20.7 | 13.7 | −8.0 |
Margins, returns, debt, tax and cash.
| Line | FY18 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 0.2% | -7.5% | 1.9% | 2.0% | 0.9% | 2.2% | 2.4% | 2.0% |
| Operating margin | 8.2% | 2.8% | 9.8% | 8.3% | 8.3% | 9.3% | 9.8% | 10.2% |
| Return on equity | – | – | – | – | 4.1% | 10.7% | 9.3% | 7.6% |
| Return on capital employed | – | – | – | – | 8.7% | 11.6% | 9.7% | 9.4% |
| Return on assets | – | – | – | – | 0.8% | 2.3% | 2.2% | 1.7% |
| Debt to equity | – | – | – | – | 2.05 | 2.02 | 1.94 | 1.94 |
| Interest coverage | 1.30 | -0.10 | 1.30 | 1.90 | 1.40 | 1.60 | 1.30 | 1.40 |
| Debt to assets | – | – | – | – | 0.42 | 0.44 | 0.45 | 0.42 |
| Current ratio | – | – | – | – | 1.09 | 1.15 | 1.07 | 1.05 |
| Quick ratio | – | – | – | – | 0.62 | 0.72 | 0.60 | 0.59 |
| Cash ratio | – | – | – | – | 0.01 | 0.02 | 0.01 | 0.01 |
| Asset turnover | – | – | – | – | 0.97 | 1.06 | 0.90 | 0.83 |
| Fixed asset turnover | – | – | – | – | 4.89 | 5.51 | 4.27 | 4.06 |
| Inventory turnover | – | – | – | – | – | 2.20 | 1.50 | 1.40 |
| Receivables turnover | – | – | – | – | 3.20 | 3.40 | 3.30 | 3.30 |
| Gross margin | – | – | – | – | – | 43.5% | 47.9% | 49.3% |
| Cash from operations to profit | – | – | – | 571.0% | – | – | 287.0% | 491.0% |
| Effective tax rate | 87.2% | – | – | 37.9% | 44.7% | 17.8% | – | – |
Dividend Payment Update - Intimation regarding disbursement of final dividend for the FY 2025 26 and withholding of dividend in respect of shareholders with incomplete KYC/bank details or invalid, blocked or closed bank accounts
Change in Director(s) of the company.
A copy Srutinizers report of Annual General Meeting held on September 24, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 24, 2026
Significant movement in price has been observed in Bal Pharma Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the…
Significant movement in price has been observed in Bal Pharma Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the…
Confirming the allotment of Convertible Warrants on Preferential basis
Record date for the purpose of Dividend is 17-Sep-2026 and Communication to shareholders regarding TDS on Final Dividend payment
Notice of Annual General Meeting to be held on September 24, 2026
Fixation of AGM on 24th September 2026 at 11.30 AM
Clarification with respect to tentative timeline for utilization of net proceeds of Preferential Issue